These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 29779938)
1. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients. Maria AM; El-Shebiney M; El-Saka AM; Zamzam Y J Egypt Natl Canc Inst; 2018 Jun; 30(2):49-55. PubMed ID: 29779938 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002 [TBL] [Abstract][Full Text] [Related]
3. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130 [No Abstract] [Full Text] [Related]
4. p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate? Kocar M; Bozkurtlar E; Telli F; Yumuk F; Kaya H; Kocar H; Serdar Turhal N J BUON; 2014; 19(1):245-9. PubMed ID: 24659671 [TBL] [Abstract][Full Text] [Related]
5. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S J BUON; 2013; 18(1):44-50. PubMed ID: 23613387 [TBL] [Abstract][Full Text] [Related]
6. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396 [TBL] [Abstract][Full Text] [Related]
7. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779 [TBL] [Abstract][Full Text] [Related]
8. The role of p95HER2 in trastuzumab resistance in breast cancer. Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A J BUON; 2016; 21(2):382-9. PubMed ID: 27273948 [TBL] [Abstract][Full Text] [Related]
9. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer. Rigakos G; Razis E; Koliou GA; Oikonomopoulos G; Tsolaki E; Sperinde J; Chrisafi S; Zarkavelis G; Pazarli E; Batistatou A; Kourea HP; Papakostas P; Bafaloukos D; Asimakopoulou NI; Res E; Kotsakis A; Pectasides D; Koutras A; Christodoulou C; Fountzilas G Anticancer Res; 2021 Apr; 41(4):1793-1802. PubMed ID: 33813384 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571 [TBL] [Abstract][Full Text] [Related]
13. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024 [TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and survival of patients with metastatic breast cancer. Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab. Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E Oncology; 2020; 98(1):35-41. PubMed ID: 31574500 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526 [TBL] [Abstract][Full Text] [Related]
17. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625 [TBL] [Abstract][Full Text] [Related]
19. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202 [TBL] [Abstract][Full Text] [Related]
20. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M; Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]